Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's diseasea§


  • a

    Funding agencies: This work was supported by grants from the van Alkemade-Keuls Foundation and the Dutch Parkinson's Disease Society (to J.J.v.H.). These funding sources had no role in the study design, collection, analysis, and interpretation of data, or writing of the report.

  • Relevant conflicts of interest/financialdisclosures: Nothing to report.

  • §

    Full financial disclosures and author roles may be found in the online version of this article.



The A-allele of the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability.


We studied 219 patients with PD who were free of dyskinesias at baseline and underwent thorough annual examinations.


The A-allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow-up, in a dose-dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.07–4.06] and 2.81 [CI, 1.43–5.54], respectively).


This finding suggests that genetic factors may affect susceptibility to dyskinesias in PD. © 2011 Movement Disorder Society